검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belatacept |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Kidney Transplantation |
Overview Indication | Highly Sensitized Prospective Kidney Transplant Recipients |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | that significantly improves renal function and reduces metabolic complications |
MoA Biomarker | biomarker-guided dosing and integration with regulatory T- and B-cell-based therapies offer opportunities for |
PK/PD Half-life | 10 h |
PK/PD Species | Mouse, Rabbit |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rabbit |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Post-transplant diabetes mellitus after kidney transplantation: pathogenesis, risk factors, and management strategies.. Post-transplant diabetes mellitus (PTDM) affects 7-39% of kidney transplant recipients and substantially worsens cardiovascular, infectious, and allograft outcomes. Although PTDM shares core pathophysiological features with type 2 diabetes-peripheral insulin resistance and impair… |
Toxicology CRS | grade 4 |
Clinical Primary efficacy | ORR 0.432% |
Clinical ORR | 0.432% |
Clinical Result source | ClinicalTrials.gov NCT01766050 |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belatacept |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Kidney Transplantation |
Overview Indication | Highly Sensitized Prospective Kidney Transplant Recipients |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | that significantly improves renal function and reduces metabolic complications |
MoA Biomarker | biomarker-guided dosing and integration with regulatory T- and B-cell-based therapies offer opportunities for |
PK/PD Half-life | 10 h |
PK/PD Species | Mouse, Rabbit |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rabbit |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Post-transplant diabetes mellitus after kidney transplantation: pathogenesis, risk factors, and management strategies.. Post-transplant diabetes mellitus (PTDM) affects 7-39% of kidney transplant recipients and substantially worsens cardiovascular, infectious, and allograft outcomes. Although PTDM shares core pathophysiological features with type 2 diabetes-peripheral insulin resistance and impair… |
Toxicology CRS | grade 4 |
Clinical Primary efficacy | ORR 0.432% |
Clinical ORR | 0.432% |
Clinical Result source | ClinicalTrials.gov NCT01766050 |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교